

Ref No. NLL/CS/2020- 228

Date: 11.02.2020

1. National Stock Exchange of India Limited
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,
Bandra (East), MUMBAI - 400 051.

2. BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street,
MUMBAI - 400 001.

Sub: Financial Results.

**Ref: Compliance Pursuant to Regulation 33 of Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015.**


Sirs,

The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone & Consolidated Financial results for the quarter and nine months ended on December 31, 2019, which are enclosed herewith along with the Limited Review Reports of the Auditors thereon.

This is for your information and record.

Thanking you,

Yours Sincerely,
For **Nectar Lifesciences Limited**



(Sukriti Saini)
Company Secretary

Encl: a.a.

CC: - Societe de la Bourse de Luxembourg S.A.
BP 165, L-2011 Luxembourg,
Telephone: (00352) 47 79 38-1
Fax: (00352) 47 32 98

NECTAR LIFESCIENCES LIMITED




Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali), Punjab -140507, Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email :

cs@neclife.com, Website : www.neclife.com, [CIN: L24232PB1995PLC016864]

Statement of Standalone Financial Results for the period ended 31.12.2019 (Rs in Lacs)

S. No.	Particulars	Quarter Ended			Nine months ended		Year Ended
		31-Dec-19	30-Sep-19	31-Dec-18	31-Dec-19	31-Dec-18	31-Mar-19
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Income from Operations						
	Sales	73,774.56	63,702.22	82,021.24	201,790.03	223,470.55	311,492.29
	Less: GST Recovered	8,523.89	6,685.28	8,897.77	21,567.43	24,827.05	32,999.30
	Revenue from Operations	65,250.67	57,016.94	73,123.47	180,222.60	198,643.50	278,492.99
	Other operating Income	-	32.76	0.63	33.09	3.77	8.47
II	Other Income	57.71	118.88	153.36	389.37	429.29	595.53
III	Total Income (I + II)	65,308.38	57,168.58	73,277.46	180,645.06	199,076.56	279,096.99
IV	Expenses						
	(a) Cost of Materials consumed	50,375.88	45,323.33	57,199.38	138,862.93	155,063.45	222,531.73
	(b) Purchase of Stock in Trade	903.72	234.98	1,627.79	1,606.85	3,148.64	4,281.71
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	1,323.21	(763.73)	(144.11)	1,686.87	(503.00)	(4,698.55)
	(d) Employee benefits expense	2,137.08	2,131.84	2,083.65	6,265.46	6,246.72	7,989.99
	(e) Finance costs	3,107.40	3,268.47	3,599.77	9,522.70	10,947.48	14,813.37
	(f) Depreciation and amortisation expense	1,522.81	1,377.30	1,687.76	4,540.46	4,871.59	6,325.74
	(g) Other expenses	4,846.16	5,394.05	5,789.75	15,260.56	15,729.28	21,997.79
	Total Expenses (IV)	64,216.26	56,966.24	71,843.99	177,745.83	195,504.16	273,241.78
V	Profit before exceptional items and tax (III- IV)	1,092.12	202.34	1,433.47	2,899.23	3,572.40	5,855.21
VI	Exceptional Items	-	-	-	-	-	-
VII	Profit from ordinary activities before tax (V - VI)	1,092.12	202.34	1,433.47	2,899.23	3,572.40	5,855.21
VIII	Tax Expense (1) Current Tax	148.98	(135.17)	296.16	258.90	466.25	741.47
	(2) Deferred Tax	55.91	148.72	5.72	214.12	113.68	380.56
IX	Profit for the period from continuing operations (VII-VIII)	887.23	188.79	1,131.59	2,426.21	2,992.47	4,733.18
	Other Comprehensive Income						
	Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	-	-	-	-	2.60
	Items that will be reclassified subsequently to profit or loss						
	Foreign Exchange Translation Reserve (Net of Tax)	-	-	-	-	-	-
	Total Other Comprehensive Income, (Net of Tax)	-	-	-	-	-	2.60
	Total Comprehensive Income for the period	887.23	188.79	1,131.59	2,426.21	2,992.47	4,735.78
X	Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)						
	a) Basic	0.40	0.08	0.50	1.08	1.33	2.11
	b) Diluted	0.40	0.08	0.50	1.08	1.33	2.11



M.No-82808

037
037

2808

